retatrutide triple agonist clinical trials Today, we shared new data from two Phase 3 of retatrutide, our investigational agonist. Learn more: https://go.lilly.com/msrz1v retatrutide Dosing Explained: What You

(c) A ELISA was conducted to detect A40 and A42 in conditioned medium from APP23 neurons

There is some risk for pancreatitis, in rare cases, but we have not yet had adverse events in our study, and the outcomes are very promising

Brand name GLP-1s like Ozempic, Trulicity, and Victoza (among others) have long been used in the treatment of type 2 diabetes specifically

Importantly, the nuance in offering GLP-1s is that employers want to ensure they get into the hands of the employees that stand to benefit most and thus get the most value out of the medicines, so I expect we will see additional restrictions put in place to control coverage of these medicines, in the form of prior authorizations and other controlled access